

ORIGINAL ARTICLE

KIR haplotypes are associated with late-onset type 1 diabetes in European–American families

JA Traherne^{1,2,6}, W Jiang^{2,6}, AM Valdes³, JA Hollenbach⁴, J Jayaraman², JA Lane⁵, C Johnson², J Trowsdale^{1,2} and JA Noble⁵

Classical human leukocyte antigens (HLA) genes confer the strongest, but not the only, genetic susceptibility to type 1 diabetes. Killer cell immunoglobulin-like receptors (KIR), on natural killer (NK) cells, bind ligands including class I HLA. We examined presence or absence, with copy number, of *KIR* loci in 1698 individuals, from 339 multiplex type 1 diabetes families, from the Human Biological Data Interchange, previously genotyped for HLA. Combining family data with *KIR* copy number information allowed assignment of haplotypes using identity by descent. This is the first disease study to use KIR copy number typing and unambiguously define haplotypes by gene transmission. *KIR* A1 haplotypes were positively associated with T1D in the subset of patients without the high T1D risk HLA genotype, DR3/DR4 (odds ratio = 1.29, $P = 0.0096$). The data point to a role for KIR in type 1 diabetes risk in late-onset patients. In the top quartile (age of onset > 14), *KIR* A2 haplotype was overtransmitted (63.4%, odds ratio = 1.73, $P = 0.024$) and *KIR* B haplotypes were undertransmitted (41.1%, odds ratio = 0.70, $P = 0.0052$) to patients. The data suggest that inhibitory 'A' haplotypes are predisposing and stimulatory 'B' haplotypes confer protection in both DR3/DR4-negative and late-onset patient groups.

Genes and Immunity (2016) 17, 8–12; doi:10.1038/gene.2015.44; published online 22 October 2015

INTRODUCTION

Type 1 diabetes is an autoimmune disorder in which the insulin-producing cells of the pancreas are destroyed, resulting in a requirement for exogenous insulin for survival. Although >40 genetic loci are implicated in type 1 diabetes susceptibility, genes encoding the human leukocyte antigens (HLA) are the strongest genetic contributors.¹ Killer cell immunoglobulin-like receptors (KIR) are found on the surface and regulate the function of Natural Killer (NK) cells, CD8+ and CD4+ $\alpha\beta$ T cells as well as $\gamma\delta$ T cells.² Inhibitory KIR (KIR2DL and KIR3DL groups) have immunoreceptor tyrosine-based motifs within their long cytoplasmic tail. Activating KIR (KIR2DS and KIR3DS groups) have shorter cytoplasmic tails that are coupled via a charged residue in the transmembrane region to adaptor proteins, such as DAP12, which contain immunoreceptor tyrosine-based activating motifs. Ligands for KIR include class I HLA. HLA class I alleles are associated with type 1 diabetes, thus providing a biological rationale to investigate KIR association with type 1 diabetes.³ KIR haplotypes fall into two types: 'A,' containing mostly inhibitory genes; and 'B,' containing one or more activating KIR genes. Common haplotypes include centromeric (cen) and telomeric (tel) KIR gene groups, exhibiting strong linkage disequilibrium within, but not between, groups (Figure 1). The telomeric A (tA) group includes *KIR2DS4*, which is the only potentially short-tailed activating KIR on the A haplotype. However, *KIR2DS4* is disabled by a 22 bp frameshift deletion in exon 5 on the majority of Caucasian A haplotypes. This distinction defines tA01 (*KIR2DS4* full length) and tA02 (*KIR2DS4* deletion variant). A small number of studies have reported KIR association with type 1 diabetes; however, most are small case–control studies

that focus on individual *KIR* genes and test only the presence or absence of *KIR* loci.⁴ A recent, larger study reports a method for imputation of *KIR* copy number for one *KIR* locus using GWAS SNP data but reports no significant type 1 diabetes association.⁵ In the current study, we performed *KIR* genotyping, with copy number determination, on a set of type 1 diabetes multiplex families that we previously genotyped for HLA class I and class II loci.⁶ This unique combination of family-based data with complete HLA and *KIR* copy number genotyping allows inference of individual haplotypes, based on identity by descent, for both *KIR* and HLA. We tested association of *KIR* haplotypes with type 1 diabetes in samples where full HLA context was known. Further, we tested those patients not carrying the highest-risk HLA genotype, that is, heterozygotes for *DRB1*03:01-DQA1*05:01-DQB1*02:01* and *DRB1*04:01/02/04/05/08-DQA1*03:01-DQB1*03:02* (referred to as 'DR3/DR4') separately from the patients who do carry the high-risk genotype. Finally, given that HLA is associated with age of onset for type 1 diabetes,⁷ we examined the *KIR* genotyping data for association with age of disease onset.

RESULTS

All families in the Human Biological Data Interchange (HBDI) data set were complete, with two parents and at least two affected siblings. All individuals were genotyped for *KIR* presence or absence and copy number for each locus.⁸ All samples were previously genotyped for the loci HLA-*DRB1*, -*DQA1*, -*DQB1*, -*DPB1*, -*A*, -*B* and -*C* and exhibited Mendelian inheritance. Both HLA and *KIR* haplotypes were inferred using identity by descent. Common *KIR* haplotypes are illustrated schematically in Figure 1.

¹Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, UK; ²Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK; ³Academic Rheumatology, University of Nottingham, City Hospital, Nottingham, UK; ⁴Department of Neurology, University of California San Francisco School of Medicine, San Francisco, CA, USA and ⁵Children's Hospital Oakland Research Institute, Oakland, California, USA. Correspondence: Dr JA Noble, Children's Hospital Oakland Research Institute, 5700 Martin Luther King, Jr. Way, Oakland, CA 94609, USA. Email: jnoble@chori.org

⁶These authors contributed equally to this work.

Received 5 June 2015; revised 14 September 2015; accepted 15 September 2015; published online 22 October 2015




Figure 1. Schematic representation of common KIR haplotypes, with the predisposing tA01 gene group boxed in red. The gene content of tA01 and tA02 are the same, except that tA01 carries the 22 bp frameshift deletion form of *KIR2DS4* (2DS4v; 2DS4*003, *004, *006, *007, *008, *009, *010, *012, *013), whereas tA02 encodes the full-length gene (2DS4f). Figure adapted from Jiang *et al.*⁸

Full haplotypes, containing both centromeric and telomeric portions, showed marginally significant overtransmission of *KIR* A1 haplotypes to affected individuals ($P=0.0494$). Separate analysis of centromeric and telomeric components of the *KIR* A1 haplotype (cA01 and tA01) revealed overtransmission of both to affected individuals, although neither result reached statistical significance. T1D patients were grouped into those who carry the very high-risk HLA class II genotype known as 'DR3/4' (*DRB1**03:01-*DQA1**05:01-*DQB1**02:01 and *DRB1**04:01/02/04/05/08-*DQA1**03:01-*DQB1**03:02/04 or *02:01) and those who do not ('non-3/4'). Transmission Disequilibrium Test (TDT) analyses revealed no significant transmission distortion in the high-risk DR3/4 group for any *KIR* haplotype tested. However, *KIR* A1-positive association with T1D was observed in the non-3/4 group, in which the HLA class II attributable risk is lower ($P=0.0096$, Table 1). Analysis of the data with Unphased 3.1.6 software also revealed this association ($P=0.006$, not shown). Separate analysis of telomeric and centromeric haplotypes showed significant overtransmission of the tA01 ($P=0.0169$, Table 1; Unphased: $P=0.003$, not shown). tA01 is included in ~55% of common *KIR* haplotypes in European populations (Figure 1). To test the hypothesis that *KIR3DL1* may contribute to the T1D predisposing effect observed for tA01, the data were stratified by the presence or absence of HLA-Bw4, the ligand for *KIR3DL1*. Both the Bw4-positive and Bw4-negative subsets had overtransmission of tA01 (54.5% and 55.2%, odds ratio=1.23 and 1.20, respectively), with the Bw4-negative result reaching the threshold for statistical significance ($P=0.05$; data not shown). The fact that tA01 overtransmission is observed either in the presence or absence of the ligand for *KIR3DL1* suggests that the *KIR3DL1*-Bw4 interaction is not the basis for the disease association of the tA01 haplotype.

HLA-C alleles can be divided into two groups, C1 and C2, depending on the identity of the amino-acid residues at position 77 and 80. HLA C2 alleles, which are ligands for 2DS1 and 2DL1, are underrepresented in T1D, whereas C1 alleles, which are ligands for 2DL2, 2DL3 and 2DS2 (weak interaction), are overrepresented.⁴ Data from the current study were consistent with that report; C2 was undertransmitted (frequency transmitted = 0.291, frequency not transmitted = 0.336) to affected individuals, whereas C1 was overtransmitted (f-trans 0.709, f-not trans = 0.66;

$P=0.000139$) (data not shown). However, testing for gene-gene interaction between HLA-C allele groups and *KIR* loci showed no evidence of interaction for any *KIR* locus with C1 or C2 (data not shown).

HLA genes, particularly class I, are associated with age of onset for T1D, suggesting that *KIR* loci may also be associated in this manner. Mean age of onset for T1D patients was 11.22 years (range 0–36 years, s.d. = 7.57; 95%CI = 10.66–11.79); median age of onset was 10 years. Patients were grouped into four age of onset categories: (1) >0 and ≤5 ($n=181$); (2) >5 and <10 ($n=156$); (3) ≥10 and ≤14 ($n=197$), (4) >14 ($n=167$). Analysis of patients in the top age of onset quartile (>14 years) revealed significant transmission distortion for several *KIR* haplotypes, including A2 (63.4%, p [TDT] = 0.024; p [Unphased] = 0.044) and B (41.1%, p [TDT] = 0.0052; p [Unphased] = 0.001), Table 2). No significant over- or undertransmission of *KIR* A and B haplotypes was observed in patients with age of onset 14 or younger. Notably, the *KIR* haplotypes that are associated in the over 14 age group (A2 and B, Table 2) differ from those that are associated in the non-DR3/4 group (A1, and more specifically, tA01, Table 1), although all data were consistent with overtransmission of *KIR* A haplotypes and undertransmission of *KIR* B haplotypes.

DISCUSSION

The fact that some HLA class I molecules are ligands for *KIR* leads to the notion that *KIR* may have a role in T1D susceptibility. Published reports of *KIR* association studies with T1D have little consistency among findings for particular loci (see allele frequencies.net/diseases⁴ and references therein). Most are small case-control studies based only on presence or absence of individual *KIR* loci. The results reported in the current study are based on *KIR* haplotypes, inferred using identity by descent from family-based data, rather than on individual loci.

Our finding that the predisposing effect of the tA01 haplotype is more pronounced in the subset of T1D patients not carrying the high-risk DR3/DR4 genotype increases our confidence that the observed predisposing effect is real. This is consistent with previous studies of T1D risk loci other than HLA-DR- and DQ-encoding genes, including *TCF7*, *IL-4R* and *PTPN22*, where

Table 1. TDT analysis of full, centromeric and telomeric *KIR* haplotypes for type 1 diabetes association with stratification by DR3/4 status

<i>KIR</i> Haplotype ^a	Trans	N-trans	TDTtest ^b	P-value ^c	Trans %	OR (95% CI)
<i>A B full, non-DR3/4</i>						
A1	236	183	6.70	0.0096	56.3%	1.29 (1.06–1.56)
A2	91	91	0.00	1.00	50.0%	1.00 (0.75–1.34)
B	283	314	1.61	0.20	47.4%	0.90 (0.77–1.06)
Others	37	59	5.04	0.0247	38.5%	0.63 (0.42–0.95)
<i>A B full, DR3/4</i>						
A1	128	121	0.20	0.66	51.4%	1.06 (0.83–1.36)
A2	53	53	0.00	1.00	50.0%	1.00 (0.68–1.46)
B	185	198	0.44	0.51	48.3%	0.93 (0.76–1.14)
Others	31	25	0.64	0.42	55.4%	1.24 (0.73–2.10)
<i>Cen haplotypes, non-DR3/4</i>						
cA01	421	381	2.00	0.16	52.5%	1.10 (0.96–1.27)
cB01	109	117	0.28	0.59	48.2%	0.93 (0.72–1.21)
cB02	80	90	0.59	0.44	47.1%	0.89 (0.66–1.20)
Others	37	59	5.04	0.0247	38.5%	0.63 (0.42–0.95)
<i>Cen haplotypes, DR3/4</i>						
cA01	232	220	0.32	0.57	51.3%	1.05 (0.88–1.27)
cB01	67	87	2.60	0.11	43.5%	0.77 (0.56–1.06)
cB02	67	65	0.03	0.86	50.8%	1.03 (0.73–1.45)
Others	31	25	0.64	0.42	55.4%	1.24 (0.73–2.10)
<i>Tel haplotypes, non-DR3/4</i>						
tA01	324	266	5.70	0.0169	54.9%	1.22 (1.04–1.43)
tA02	142	149	0.17	0.68	48.8%	0.95 (0.76–1.20)
tB01	144	173	2.65	0.10	45.4%	0.83 (0.67–1.04)
Others	37	59	5.04	0.0247	38.5%	0.63 (0.42–0.95)
<i>Tel haplotypes, DR3/4</i>						
tA01	181	189	0.17	0.68	48.9%	0.96 (0.78–1.17)
tA02	93	98	0.13	0.72	48.7%	0.95 (0.71–1.26)
tB01	92	85	0.28	0.60	52.0%	1.08 (0.81–1.45)
Others	31	25	0.64	0.42	55.4%	1.24 (0.73–2.10)

Abbreviations: CI, confidence interval; OR, odds ratio. ^aA B Full = haplotypes containing both the centromeric and telomeric groups. A1 = 3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4FL-3DL2; A2 = 3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4FL-3DL2; B = haplotypes with at least one activating *KIR* gene; cA01 = 3DL3-2DL3-2DP1-2DL1-3DP1; cB01 = 3DL3-2DS2-2DL2-3DP1; cB02 = 3DL3-2DS2-2DL2-2DL5C-2DS3S5C-2DP1-2DL1-3DP1; tA01 = 2DL4-3DL1-2DS4FL-3DL2; tA02 = 2DL4-3DL1-2DS4FL-3DL2; tB01 = 2DL4-3DS1-2DL5-2DS3S5T-2DS1-3DL2; others: haplotypes with frequency < 1.0%. ^bTDT tests were performed separately for each affected sibling in a family. Testing using an average of the two siblings for each family gave similar results; however, the *P*-values did not reach statistical significance. ^cSignificant *P*-values (> 0.05) are indicated with bold type. *P*-values are uncorrected based on prior hypothesis for *KIR*-T1D association. Trans, number of transmitted haplotypes; N-trans, number of untransmitted haplotypes.

the effect of the risk allele was stronger in the non-DR3/4 patients than in the DR3/4 group.

One report of functional studies in the NOD mouse model of T1D suggests that expression of the inhibitory receptor *KIR3DL1* predisposes NOD mice to diabetes by downregulating function of regulatory T cells.⁹ *KIR3DL1* is found on telomeric *KIR* A haplotypes; thus, our finding that tA01 haplotypes are predisposing for T1D is consistent with the NOD result. If the dominance of the inhibitory or educative activity of *KIR3DL1* is important then presumably this should only be apparent when an appropriate HLA ligand (Bw4+) is also present. Although no statistically significant transmission distortion was observed in the HBDI data set for *KIR* in the context of HLA class I ligands, the combination of *KIR3DL1* with the gene for Bw4-80I (Bw4 molecules that have isoleucine at dimorphic position 80, which show stronger interaction with *KIR3DL1* receptors than Bw4 molecules that have threonine in this position (Bw4-80T)^{10,11}) exhibited the highest transmission percentage at 54.7% (odds ratio = 1.21, 95% CI 0.92–1.59). Using a combination of *KIR* copy number typing and SNP imputation of *KIR* copy number, Pontikos *et al.*⁵ report no association of 3DL1/3DS1 with T1D in a large case–control study; however, cases were not stratified by HLA, and age of onset for all subjects was less than 17. Although no firm conclusion about the risk effect of *KIR3DL1*

on T1D can be made, the combination of evidence from genetic and animal models warrants further study of this locus. An alternative explanation for the tA01 association could relate to the presence of the *KIR2DS4v* gene that encodes a soluble and potentially secreted form of the protein. This may be biologically relevant if it antagonizes the effects of other *KIRs*.¹²

These haplotype-based data suggest that *KIR* genes have a role in T1D susceptibility. This study was powered with the assumption that *KIR* haplotype effects might be similar in magnitude to those of class I *HLA*; however, the effect of *KIR* diversity on T1D susceptibility appears to be modest. This does not rule out the possibility that individual *KIR* loci or haplotypes may have a substantial effect in a subset of patients. The data point to a role for *KIR* in type 1 diabetes risk in older onset patients, which has been missed in other studies. The fact that the A2 haplotype is more strongly associated with older age of onset than is the A1 haplotype suggests that the cell-surface receptor *KIR2DS4* may have a role. However, in these data, patients who have at least one copy of *KIR2DS4* appear equally likely to have at least one ligand for that receptor (*C*01:02*, **02:02*, **04:01*, **05:01*, **14:02* or **16:01*) in the ≤14 age of onset group compared with the >14 age of onset group (32% vs 33%, data not shown). A larger data set is needed to test each ligand independently. The data from this

Table 2. TDT analysis of full, centromeric and telomeric *KIR* haplotypes for type 1 diabetes association with stratification by age of onset

<i>KIR</i> Haplotype ^a	<i>Trans</i>	<i>N-trans</i>	<i>TDTtest</i> ^b	<i>P-value</i> ^c	<i>Trans %</i>	<i>OR (95% CI)</i>
<i>A B full, age onset ≤ 14</i>						
A1	265	228	2.78	0.10	53.8%	1.16 (0.97–1.39)
A2	96	117	2.07	0.15	45.1%	0.82 (0.63–1.07)
B	362	361	0.00	0.97	50.1%	1.00 (0.87–1.16)
Others	45	62	2.70	0.10	42.1%	0.73 (0.49–1.07)
<i>A B full, age onset > 14</i>						
A1	95	70	3.79	0.0516	57.6%	1.36 (1.00–1.85)
A2	45	26	5.08	0.0241	63.4%	1.73 (1.07–2.80)
B	102	146	7.81	0.0052	41.1%	0.70 (0.54–0.90)
Others	20	20	0.00	1.00	50.0%	1.00 (0.54–1.86)
<i>Cen haplotypes, age onset ≤ 14</i>						
cA01	472	453	0.39	0.53	51.0%	1.04 (0.92–1.19)
cB01	139	147	0.22	0.64	48.6%	0.95 (0.75–1.19)
cB02	112	106	0.17	0.68	51.4%	1.06 (0.81–1.38)
Others	45	62	2.70	0.10	42.1%	0.73 (0.49–1.07)
<i>Cen haplotypes, age onset > 14</i>						
cA01	173	140	3.48	0.0621	55.3%	1.24 (0.99–1.54)
cB01	37	56	3.88	0.0488	39.8%	0.66 (0.44–1.00)
cB02	32	46	2.51	0.11	41.0%	0.70 (0.44–1.09)
Others	20	20	1.00	1.00	50.0%	1.00 (0.54–1.86)
<i>Tel haplotypes, age onset ≤ 14</i>						
tA01	375	333	2.49	0.11	53.0%	1.13 (0.97–1.31)
tA02	166	191	1.75	0.19	46.5%	0.87 (0.71–1.07)
tB01	182	182	0.00	1.00	50.0%	1.00 (0.81–1.23)
Others	45	62	2.70	0.10	42.1%	0.73 (0.49–1.07)
<i>Tel haplotypes, age onset > 14</i>						
tA01	123	112	0.51	0.47	52.3%	1.10 (0.85–1.42)
tA02	66	55	1.00	0.32	54.5%	1.20 (0.84–1.72)
tB01	53	75	3.78	0.0518	41.4%	0.71 (0.50–1.00)
Others	20	20	0.00	1.00	50.0%	1.00 (0.54–1.86)

^aA B Full = haplotypes containing both the centromeric and telomeric groups. A1 = 3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4Del-3DL2; A2 = 3DL3-2DL3-2DP1-2DL1-3DP1-2DL4-3DL1-2DS4FL-3DL2; B = haplotypes with at least one activating *KIR* gene; cA01 = 3DL3-2DL3-2DP1-2DL1-3DP1; cB01 = 3DL3-2DS2-2DL2-3DP1; cB02 = 3DL3-2DS2-2DL2-2DL5C-2DS3S5C-2DP1-2DL1-3DP1; tA01 = 2DL4-3DL1-2DS4Del-3DL2; tA02 = 2DL4-3DL1-2DS4FL-3DL2; tB01 = 2DL4-3DS1-2DL5-2DS3S5T-2DS1-3DL2; Others: haplotypes with frequency < 1.0%. ^bTDT tests were performed separately for each affected sibling in a family. Testing using an average of the two siblings for each family gave similar results; however, the *P*-values did not reach statistical significance. ^cSignificant *P*-values (> 0.05) are indicated with bold type. *P*-values are uncorrected based on prior hypothesis for *KIR*-T1D association. *Trans*, number of transmitted haplotypes; *N-trans*, number of untransmitted haplotypes.

report support the notion that *KIR* A haplotypes, which contain mostly inhibitory *KIR* genes, are predisposing for T1D, whereas *KIR* B haplotypes, which contain more activating *KIR* loci, are protective. Activating *KIR* could act by stimulating regulatory T cells to control disease, or by influencing NK killing of effector T cells. On the other hand, inhibitory *KIR* could constrain the action of T1D-specific regulatory T cells, or fail to control cytotoxic T cells, allowing disease progression. In contrast with autoimmune diabetes in children, where HLA predominates, the genetics of autoimmune diabetes in adults are not well understood, despite its relatively high prevalence. Our finding will potentially be useful to better categorize patients in the future and to probe the influence of *KIR* on NK/T cells and autoantigen-specific regulatory T cells. Given the complexity of both the *HLA* and *KIR* genetic loci, and extreme variability of both among populations, a thorough understanding of the role of *KIR* genes and haplotypes in T1D will require very large sample sets, where individual subsets are large enough to uncover potential highly significant results.

SUBJECTS AND METHODS

The HBDI is a repository for families including children with T1D (National Disease Research Interchange; <http://ndriresource.org/Donor-Programs/Family-Genetics-HBDI/36/>). These families were previously genotyped for

the loci *HLA-DRB1*, *-DQA1*, *-DQB1*, *-DPB1*, *-A*, *-B* and *-C* and were analyzed extensively for T1D association.^{6,13} The 339 families in this study are multiplex, that is, include more than one affected child. Parents are unaffected. All families exhibit Mendelian inheritance. HBDI families were genotyped for *HLA* class I and class II at two-field (four digit) resolution by polymerase chain reaction sequence-specific oligonucleotide probe (PCR-SSO) technology as previously described.^{6,13} *KIR* genotype and copy number were measured using a quantitative PCR comparative Ct method developed from a protocol for determining genomic copy number as described earlier.⁸ Reactions were carried out in quadruplicate to ensure accuracy of the copy number scoring. Identity by descent-inferred *KIR* haplotypes were determined using the Merlin program as previously described.⁸ A TDT was applied to the data (two-sided test). Each family was analyzed as trios for each affected sibling. Odds ratios and 95% confidence intervals were estimated using the proportion T of transmitted risk allele as described.¹⁴ The estimate of the odds ratio is given by: $T/(1-T)$. In addition, Unphased software 3.1.6¹⁵ was used to perform the association analyses using the allelmain model, which is robust to the issue of the non-independence of individuals in a sibling pair. The gxx model of the Unphased software was used to test gene–gene interaction between *HLA* allele groups and *KIR* loci. *P*-values are uncorrected based on prior hypothesis for *KIR*-T1D association.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported in part by National Institutes of Health award R01 DK61722 (JAN). Research in the Trowsdale lab is supported by the MRC and Wellcome Trust with part funding from the National Institute for Health Research Cambridge Biomedical Research Centre. JAN is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

REFERENCES

- Noble JA. Immunogenetics of type 1 diabetes: a comprehensive review. *J Autoimmun* 2015; e-pub ahead of print 10 August 2015; doi:10.1016/j.jaut.2015.07.014.
- Bjorkstrom NK, Beziat V, Cichocki F, Liu LL, Levine J, Larsson S *et al*. CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells. *Blood* 2012; **120**: 3455–3465.
- Noble JA, Valdes AM, Varney MD, Carlson JA, Moonsamy P, Fear AL *et al*. HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. *Diabetes* 2010; **59**: 2972–2979.
- Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL *et al*. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. *Nucleic Acids Res* 2015; **43**: D784–D788.
- Pontikos N, Smyth DJ, Schuilenburg H, Howson JM, Walker NM, Burren OS *et al*. A hybrid qPCR/SNP array approach allows cost efficient assessment of KIR gene copy numbers in large samples. *BMC Genomics* 2014; **15**: 274.
- Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. *Am J Hum Genet* 1996; **59**: 1134–1148.
- Valdes AM, Erlich HA, Carlson J, Varney M, Moonsamy PV, Noble JA. Use of class I and class II HLA loci for predicting age at onset of type 1 diabetes in multiple populations. *Diabetologia* 2012; **55**: 2394–2401.
- Jiang W, Johnson C, Jayaraman J, Simecek N, Noble J, Moffatt MF *et al*. Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors. *Genome Res* 2012; **22**: 1845–1854.
- Qin H, Wang Z, Du W, Lee WH, Wu X, Riggs AD *et al*. Killer cell Ig-like receptor (KIR) 3DL1 down-regulation enhances inhibition of type 1 diabetes by autoantigen-specific regulatory T cells. *Proc Natl Acad Sci USA* 2011; **108**: 2016–2021.
- Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. *J Immunol* 2005; **175**: 5222–5229.
- Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. *J Exp Med* 1994; **180**: 1235–1242.
- Middleton D, Gonzalez A, Gilmore PM. Studies on the expression of the deleted KIR2DS4*003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations. *Hum Immunol* 2007; **68**: 128–134.
- Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P *et al*. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. *Diabetes* 2008; **57**: 1084–1092.
- Kazeem GR, Farrall M. Integrating case-control and TDT studies. *Ann Hum Genet* 2005; **69**: 329–335.
- Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. *Hum Hered* 2008; **66**: 87–98.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>